Designing Grade A environments for drug development through to full manufacture

Published: 5-Feb-2016

Pharmaceutical manufacturers are under increasing pressure to guarantee drug sterility. Simon Phillips, Head of Sterile Manufacturing, Nova Laboratories, explains how designing the right Grade A environment at a drug’s development stage can alleviate pressure further down the line

You need to be a subscriber to read this article.
Click here to find out more.

For two decades Nova Laboratories has provided clinical trial supplies to a global customer base. In this time the company has developed expertise in the use of high-integrity, gassed isolator technology which has been acknowledged by various regulators as ‘best practice’. The company’s work on complex and novel aseptic processes and clinical manufacturing of parenterals and devices has enabled it to develop commercial manufacturing processes for specialist sterile products that are to be marketed following successful clinical trials.

The company can design, construct and develop bespoke isolators, cleanrooms and associated process equipment for customers and boasts more than two million media fill simulations to date across a range of complex presentations with zero failure rate. This high level of sterility assurance is obtained by a combination of isolator design, use of highly trained staff, strict controls for the sterilisation of components, process design and the careful selection of suitable equipment for complex sterile processing.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.

Subscribe now Already a subscriber? Sign in here.

You may also like